{
    "data": [
        {
            "id": "4312928",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-17T12:41:17-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's CAR-T Therapy Targeting BCMA Proves Itself In Treating Highly Refractory Multiple Myeloma Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "247852",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4312928-johnson-and-johnsons-car-t-therapy-targeting-bcma-proves-in-treating-highly-refractory"
            }
        },
        {
            "id": "4300997",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-31T14:15:06-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Xarelto Gains Another FDA Approved Indication, Needs Additional Nods Under Its Belt",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "77935",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4300997-johnson-and-johnsons-xarelto-gains-another-fda-approved-indication-needs-additional-nods"
            }
        },
        {
            "id": "4299984",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-29T14:08:59-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson: A Undervalued Dividend King With Some Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "77019",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299984-buy-johnson-and-johnson-undervalued-dividend-king-risks"
            }
        },
        {
            "id": "4299490",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-28T03:13:38-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Inconsistent Matter Of Management, The Credo, And The Talc Problem",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102540",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "76792",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299490-johnson-and-johnson-inconsistent-matter-of-management-credo-and-talc-problem"
            }
        },
        {
            "id": "4297883",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-22T12:54:25-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why You Must Look At Fairly-Valued Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75523",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4297883-why-you-must-look-fairly-valued-johnson-and-johnson"
            }
        },
        {
            "id": "4297718",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-21T18:58:29-04:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Yield Still Not Worth The Legal Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75451",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4297718-johnson-and-johnson-yield-still-not-worth-legal-risk"
            }
        },
        {
            "id": "4297527",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-21T06:10:31-04:00",
                "isLockedPro": false,
                "commentCount": 179,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Overthink It, Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75494",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4297527-dont-overthink-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4297220",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-18T02:15:17-04:00",
                "isLockedPro": false,
                "commentCount": 127,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Impossible Beckons",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "74973",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4297220-johnson-and-johnson-impossible-beckons"
            }
        },
        {
            "id": "4295666",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-08T20:52:53-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Nod For Prostate Cancer Drug May Offer Hope To Specific Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "73146",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4295666-johnson-and-johnsons-nod-for-prostate-cancer-drug-may-offer-hope-to-specific-patients"
            }
        },
        {
            "id": "4294306",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-01T06:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend King: Johnson & Johnson Poised For Another Dividend Boost",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32121",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "71187",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4294306-dividend-king-johnson-and-johnson-poised-for-another-dividend-boost"
            }
        },
        {
            "id": "4292728",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-20T14:26:36-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Portfolio: Halftime Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "68855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4292728-johnson-and-johnson-portfolio-halftime-report"
            }
        },
        {
            "id": "4292581",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-20T07:46:00-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Opportunity Beckons - Know When To Strike",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "68425",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4292581-johnson-and-johnson-opportunity-beckons-know-when-to-strike"
            }
        },
        {
            "id": "4292058",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-17T13:30:35-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Dead Serious Opioid Issues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "65749",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4292058-johnson-and-johnsons-dead-serious-opioid-issues"
            }
        },
        {
            "id": "4290858",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-11T01:06:53-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Definitive Tests",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "63948",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4290858-johnson-and-johnsons-definitive-tests"
            }
        },
        {
            "id": "4290033",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-05T18:58:14-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: An Emerging Sum Of The Parts Investment Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105387",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "64940",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4290033-johnson-and-johnson-emerging-sum-of-parts-investment-case"
            }
        },
        {
            "id": "4289330",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-03T11:04:06-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Breaking Down The Oklahoma Johnson & Johnson Opioid Verdict",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "63824",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4289330-breaking-down-oklahoma-johnson-and-johnson-opioid-verdict"
            }
        },
        {
            "id": "4281557",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-05T05:52:17-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Resilience Makes It A Top Recession Pick",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56851",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4281557-johnson-and-johnsons-resilience-makes-top-recession-pick"
            }
        },
        {
            "id": "4280877",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-02T15:18:00-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arrowhead Pharmaceuticals - Janssen Collaboration Could Be A Game Changer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101571",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56711",
                            "type": "sentiment"
                        },
                        {
                            "id": "56712",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4280877-arrowhead-pharmaceuticals-janssen-collaboration-be-game-changer"
            }
        },
        {
            "id": "4278312",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-27T07:30:11-04:00",
                "isLockedPro": false,
                "commentCount": 113,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Buy-And-Hold Forever Stocks For Rising Dividend Income",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55102",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278312-4-buy-and-hold-forever-stocks-for-rising-dividend-income"
            }
        },
        {
            "id": "4278195",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-26T14:25:00-04:00",
                "isLockedPro": false,
                "commentCount": 248,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson et al: Rumored $100B Opioid Settlement Could Upend Pain Management Companies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55349",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4278195-johnson-and-johnson-et-al-rumored-100b-opioid-settlement-upend-pain-management-companies"
            }
        },
        {
            "id": "4277125",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-24T14:24:07-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "54842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4277125-johnson-and-johnsons-stock-may-be-too-cheap-in-low-interest-rate-world"
            }
        },
        {
            "id": "4276425",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-22T11:00:33-04:00",
                "isLockedPro": false,
                "commentCount": 155,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Yield Isn't Worth Legal Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "53729",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4276425-johnson-and-johnson-yield-isnt-worth-legal-risk"
            }
        },
        {
            "id": "4276179",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-20T02:08:41-04:00",
                "isLockedPro": false,
                "commentCount": 127,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Getting Attractive As It Sinks Towards $130",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "53425",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4276179-johnson-and-johnson-getting-attractive-sinks-towards-130"
            }
        },
        {
            "id": "4276133",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-19T16:42:21-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson, Dividend King With Steady Growing Defensive Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "53167",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4276133-buy-johnson-and-johnson-dividend-king-steady-growing-defensive-earnings"
            }
        },
        {
            "id": "4275652",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-18T07:36:29-04:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Good News And Bad News About Johnson & Johnson's Potential $15 Billion Talcum Powder Liabilities",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "52806",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4275652-good-news-and-bad-news-johnson-and-johnsons-potential-15-billion-talcum-powder-liabilities"
            }
        },
        {
            "id": "4275419",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-17T10:01:14-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Grade 'A' Retirement Portfolio: Johnson & Johnson Is Added To The Wait List",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "52853",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4275419-grade-a-retirement-portfolio-johnson-and-johnson-is-added-to-wait-list"
            }
        },
        {
            "id": "4274264",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-10T10:33:48-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Reasons Johnson & Johnson Is A Buy And 4 Reasons It Is Not",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50891",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274264-2-reasons-johnson-and-johnson-is-buy-and-4-reasons-is-not"
            }
        },
        {
            "id": "4273893",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-08T13:29:50-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: 8-9% Annual Total Return Potential Makes This Dividend Aristocrat A Hold",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50437",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273893-johnson-and-johnson-8minus-9-percent-annual-total-return-potential-makes-this-dividend"
            }
        },
        {
            "id": "4272698",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-28T14:20:42-04:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Value Appraisal With The Talc Lawsuits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "42661",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48657",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272698-johnson-and-johnson-value-appraisal-talc-lawsuits"
            }
        },
        {
            "id": "4272220",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T12:15:22-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks To Blood Cancer Drug Successor With Early-Stage Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48022",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272220-johnson-and-johnson-looks-to-blood-cancer-drug-successor-early-stage-deal"
            }
        },
        {
            "id": "4271667",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-24T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Search For Dividend Safety: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46888",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271667-search-for-dividend-safety-johnson-and-johnson"
            }
        },
        {
            "id": "4271050",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-19T11:56:05-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Building A Bulletproof Portfolio Around Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46410",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271050-building-bulletproof-portfolio-around-johnson-and-johnson"
            }
        },
        {
            "id": "4267805",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-02T14:57:13-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson - Experiencing Buyer's Remorse",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "84276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "41659",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4267805-johnson-and-johnson-experiencing-buyers-remorse"
            }
        },
        {
            "id": "4267606",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-31T14:13:26-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Shareholder-Friendly, With A Caveat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "41653",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4267606-johnson-and-johnson-shareholder-friendly-caveat"
            }
        },
        {
            "id": "4257837",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-29T20:07:32-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Comes Out Of Gate With First Approval For Targeted Bladder Cancer Therapy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34365",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4257837-johnson-and-johnson-comes-out-of-gate-first-approval-for-targeted-bladder-cancer-therapy"
            }
        },
        {
            "id": "4256159",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-24T03:43:43-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Things To Consider Before Buying Johnson & Johnson At $140",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "33075",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4256159-things-to-consider-buying-johnson-and-johnson-140"
            }
        },
        {
            "id": "4255101",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-17T22:02:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "31869",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4255101-johnson-and-johnson-looks-to-help-type-2-diabetes-patients-key-advancement"
            }
        },
        {
            "id": "4253889",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-11T03:05:59-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Solid, Stable Returns, But Pfizer A Better Prospect",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "29760",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253889-johnson-and-johnson-solid-stable-returns-pfizer-better-prospect"
            }
        },
        {
            "id": "4251061",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-26T12:27:24-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Pfizer: Which Big Pharma Giant Is The Better Dividend Stock?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "26009",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251061-johnson-and-johnson-vs-pfizer-which-big-pharma-giant-is-better-dividend-stock"
            }
        },
        {
            "id": "4251057",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-26T11:39:00-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Forget About Talc And Focus On The Upcoming Dividend Hike",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38631",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25996",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251057-johnson-and-johnson-forget-talc-and-focus-on-upcoming-dividend-hike"
            }
        },
        {
            "id": "4248004",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-12T09:00:35-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Johnson & Johnson Is Still An Attractive Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104579",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23158",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4248004-why-johnson-and-johnson-is-still-attractive-investment"
            }
        },
        {
            "id": "4247270",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-08T07:40:35-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Brace For Impact",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104439",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "22725",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4247270-johnson-and-johnson-brace-for-impact"
            }
        },
        {
            "id": "4242213",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-19T16:32:08-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks Undervalued: Time To Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102764",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8727",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4242213-johnson-and-johnson-looks-undervalued-time-to-buy"
            }
        },
        {
            "id": "4240919",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-14T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Regulatory Headwinds Compromise Half Of Future Revenue Streams",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104177",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8015",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240919-johnson-and-johnson-regulatory-headwinds-compromise-half-of-future-revenue-streams"
            }
        },
        {
            "id": "4240332",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-12T16:33:20-05:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Dividend Blue-Chips Set To Soar And 1 You Should Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7968",
                            "type": "sentiment"
                        },
                        {
                            "id": "7969",
                            "type": "sentiment"
                        },
                        {
                            "id": "7970",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240332-2-dividend-blue-chips-set-to-soar-and-1-you-should-ignore"
            }
        },
        {
            "id": "4235692",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-25T14:54:52-05:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson For Safe Increasing Income With Dividend Increase Coming In April",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235692-buy-johnson-and-johnson-for-safe-increasing-income-dividend-increase-coming-in-april"
            }
        },
        {
            "id": "4235217",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-25T07:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Healing The World One Biotech Investment At A Time With Jerome Verony (Podcast)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104916",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5897",
                            "type": "sentiment"
                        },
                        {
                            "id": "5898",
                            "type": "sentiment"
                        },
                        {
                            "id": "5899",
                            "type": "sentiment"
                        },
                        {
                            "id": "5900",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4235217-healing-world-one-biotech-investment-time-jerome-verony-podcast"
            }
        },
        {
            "id": "4235394",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-24T15:14:20-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Goodbye Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5901",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235394-johnson-and-johnson-goodbye-growth"
            }
        },
        {
            "id": "4235245",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-24T09:08:00-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Covered-Call Writing With J&J",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104718",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235245-covered-call-writing-j-and-j"
            }
        },
        {
            "id": "4235062",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-23T15:27:35-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Reasons To Avoid J&J Now Relate To Other Safe Havens",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5729",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235062-reasons-to-avoid-j-and-j-now-relate-to-safe-havens"
            }
        },
        {
            "id": "4233865",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-17T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: P/E Matters",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5016",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233865-johnson-and-johnson-p-e-matters"
            }
        },
        {
            "id": "4232927",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-12T00:35:24-05:00",
                "isLockedPro": false,
                "commentCount": 124,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Remember 'Our Credo'?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102540",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4487",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4232927-johnson-and-johnson-remember-our-credo"
            }
        },
        {
            "id": "4231352",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-03T16:36:42-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Quantifying Johnson & Johnson's Contingent Liabilities",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30661",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3580",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231352-quantifying-johnson-and-johnsons-contingent-liabilities"
            }
        }
    ]
}